2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2283

Steroid-Sparing Effect of Anakinra (Kineret^®) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome
Abstract Number: 33

Stimulation of the Adenosine a_2Areceptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction
Abstract Number: L21

Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13
Abstract Number: 2468

Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
Abstract Number: 1080

Stroke Risks Among U.S. Medicaid Recipients with Systemic Lupus Erythematosus, 2000-2006: Racial and Ethnic Variation
Abstract Number: 2463

Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis
Abstract Number: 1916

Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice
Abstract Number: 566

Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 1997

Structured Integrative Rheumatology Modules (SIRM)
Abstract Number: 1379

Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis
Abstract Number: 1268

Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies
Abstract Number: 1533

Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
Abstract Number: 1226

Studying Patients with Autoinflammatory Diseases: The Past, Present, and a Perspective for the Future
Abstract Number: 1381

Subaxial Cervical Spine Involvement in Symptomatic Rheumatoid Arthritis Patients: Comparison with Cervical Spondylosis
Abstract Number: 1818

Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].